Andere Sprachen Marker Therapeutics, Inc.

Aktien

A3D5YK

US57055L2060

MRKR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
4,22 ^USD	+0,48 %		-1,63 %	-23,27 %

30.04.	MARKER THERAPEUTICS, INC. : Ladenburg Thalmann bleibt bei seiner Kaufempfehlung	ZM
25.03.	Marker Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	08.04.
North American Morning Briefing : Stocks Edge -2-	27.03.
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	25.03.
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	22.03.
North American Morning Briefing : Markets on Hold -2-	20.03.
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13.03.
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	22.01.
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	22.01.
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08.01.
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08.01.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	21.12.
Top Midday Gainers	11.12.
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	11.12.
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	11.12.
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	09.11.
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	09.11.
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	11.09.23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse	11.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Marker Therapeutics, Inc.

Aktien

A3D5YK

US57055L2060

MRKR

Andere Sprachen

Filter